Abstract Silicone breast implant is associated with complications inherent to the surgical procedure. Prosthesis coating with polyurethane, however, commonly reduces the incidence of such complications. In this paper, the authors evaluated the inflammatory histomorphometric profile and oxidative damage associated to the implant of polyester urethane sheets. Forty-eight Wistar rats were divided into Sham or polyester urethane groups (n = 8/group) and underwent a polyester urethane implant in the dorsal skinfold. Tissue samples were collected on days seven, 30, and 90 after surgery and subjected to histomorphometric analysis and biochemical tests. Results were analyzed by one-way ANOVA (p ≤ 0.05). Peri-implant tissue samples exhibited characteristic inflammatory response associated with the biomaterial, with increased vascularization on day seven and augmented levels of IL1-b and TNF-a after 30 days. Peri-implant fibrocystic population was small on day seven, but increased considerably after 90 days. A rise in the carbonyl group levels of skin samples in the polyester urethane group was observed on day seven. Findings suggest that polyester urethane sheets undergo biodegradation at an early stage after implantation, followed by increased vascularity and microencapsulation of biomaterial fragments, without persistent oxidative damage. Fiber arrangement inside the collagen matrix results in a fibrotic scar because of polyester urethane degradation.

Nós investigamos os níveis do Fator Neurotrófico Derivado do Cérebro (BDNF), citosinas e parâmetros oxidativos em soro e correlacionamos com a idade e funcionalidade dos pacientes com Distrofias Musculares Progressivas (PMD). Os pacientes foram separados em seis grupos (casos e controles pareados por idade e sexo), como segue: Distrofia Muscular de Duchenne (DMD); Distrofia Miotônica de Steinert (SMD); e Distrofia Muscular de Cinturas do tipo 2A (LGMD2A). Pacientes com DMD (±17,9 anos de idade) tiveram uma diminuição da funcionalidade, aumento nos níveis de IL-1β e TNF-α e uma diminuição dos níveis de IL-10 e da atividade da superóxido dismutase no soro. Pacientes com SMD (±25,8 anos de idade) tiveram uma diminuição dos níveis de BDNF e IL-10 e da atividade da superóxido dismutase e um aumento dos níveis de IL-1β no soro. Pacientes com LGMD2A (±27,7 anos de idade) tiveram uma diminuição somente nos níveis de IL-10 no soro. Esta pesquisa mostrou a primeira evidência do envolvimento dos níveis de BDNF em pacientes com SMD e um possível desequilíbrio entre fatores pró e antiinflamatórios de citosinas e uma diminuição da atividade da superóxido dismutase em soro de pacientes com DMD e SMD.

We investigated the levels of brain derived-neurotrophic factor (BDNF), cytokines and oxidative parameters in serum and tried to correlate them with the age and functionality of patients with Progressive Muscle Dystrophies (PMD). The patients were separated into six groups (case and controls pared by age and gender), as follows: Duchenne Muscular Dystrophy (DMD); Steinert Myotonic Dystrophy (SMD); and Limb-girdle Muscular Dystrophy type-2A (LGMD2A). DMD patients (±17.9 years old) had a decrease of functionality, an increase in the IL-1β and TNF-α levels and a decrease of IL-10 levels and superoxide dismutase activity in serum. SMD patients (±25.8 years old) had a decrease of BDNF and IL-10 levels and superoxide dismutase activity and an increase of IL-1β levels in serum. LGMD2A patients (±27.7 years old) had an decrease only in serum levels of IL-10. This research showed the first evidence of BDNF involvement in the SMD patients and a possible unbalance between pro-inflammatory and anti-inflammatory cytokine levels, along with decreased superoxide dismutase activity in serum of DMD and SMD patients.